Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bad Krozingen – page 26

689 clinical trials in Bad Krozingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Krozingen at a glance
689
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

689 trials in Bad Krozingen

Open in trial search

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Peripheral arterial occlusive disease

Not yet recruiting

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemastine Fumarate
  • Sponsor:Rheacell GmbH & Co. KG

Obesity+1

Not yet recruiting

A Phase III Study of Once‑Weekly Petrelintide to Evaluate Efficacy and Safety for Weight Loss in Adults with Overweight or Obesity

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not yet recruiting

Evaluation of Upadacitinib Re‑induction in Patients with Ulcerative Colitis Who Have Lost Response to a 30 mg Maintenance Dose

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:i-GETAID

Lichen planopilaris

Not yet recruiting

Safety and Efficacy of Oral Brepocitinib in Adults with Lichen Planopilaris: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2/3 Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Priovant Therapeutics Inc.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Bad Krozingen

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein management and preventive therapies for cardiovascular disease, exploring new treatments to reduce major cardiovascular events in high-risk patients.

  • Cardiovascular death prevention
  • Stroke prevention
  • Myocardial infarction management

Advanced studies evaluating novel therapeutic approaches for better cardiovascular outcomes.

02 Thrombosis and Embolism

Clinical investigations into deep vein thrombosis treatments and prevention of systemic embolism, particularly in patients with atrial fibrillation.

  • Clot lysis therapy
  • Pulmonary embolism treatment
  • Anticoagulation strategies

Comprehensive research on blood clot prevention and treatment methodologies.

03 Cardiac Conditions

Studies addressing hypertension management and innovative treatments for acute coronary syndromes, including specialized interventions for heart attack prevention.

  • Blood pressure control
  • Acute myocardial infarction
  • Coronary interventions

Evaluating cutting-edge therapies for various cardiac conditions.

04 Vascular Health

Research focusing on peripheral arterial disease and advanced vascular interventions, including novel contrast medium strategies for better patient outcomes.

  • Peripheral vascular interventions
  • Kidney protection strategies
  • Vascular disease management

Developing safer and more effective vascular treatment approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.